NGF Level Is Not Decreased in the Serum, Brain-Spinal Fluid, Hippocampus, or Parietal Cortex of Individuals with Alzheimer′s Disease

K. Murase, Toshitaka Nabeshima, Y. Robitaille, R. Quirion, M. Ogawa, K. Hayashi

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Although the cause of Alzheimers disease (AD) is unknown, nerve growth factor (NGF) has gained attention as a therapeutic agent for the disease. Because NGF maintains the magnocellular cholinergic neurons that are damaged in AD, research interests have been focused on the change in NGF level in patients with AD. This is the first reported study in which human NGF levels were accurately measured and compared between normal and AD samples. We measured NGF levels using enzyme immunoassay (EIA) system for human NGF and found no difference in NGF level in serum, brain-spinal fluid, or brain (hippocampus and parietal cortex) obtained from normal people and patients with AD. These results suggest that a decrease in the NGF level is not a causative factor of AD.

Original languageEnglish
Pages (from-to)198-203
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume193
Issue number1
DOIs
Publication statusPublished - 28-05-1993
Externally publishedYes

Fingerprint

Parietal Lobe
Nerve Growth Factor
Hippocampus
Brain
Alzheimer Disease
Fluids
Serum
Cholinergic Neurons
Immunoenzyme Techniques
Cholinergic Agents
Neurons
Enzymes

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

@article{b7fe419e49d243358c257cdbef2425cd,
title = "NGF Level Is Not Decreased in the Serum, Brain-Spinal Fluid, Hippocampus, or Parietal Cortex of Individuals with Alzheimer′s Disease",
abstract = "Although the cause of Alzheimers disease (AD) is unknown, nerve growth factor (NGF) has gained attention as a therapeutic agent for the disease. Because NGF maintains the magnocellular cholinergic neurons that are damaged in AD, research interests have been focused on the change in NGF level in patients with AD. This is the first reported study in which human NGF levels were accurately measured and compared between normal and AD samples. We measured NGF levels using enzyme immunoassay (EIA) system for human NGF and found no difference in NGF level in serum, brain-spinal fluid, or brain (hippocampus and parietal cortex) obtained from normal people and patients with AD. These results suggest that a decrease in the NGF level is not a causative factor of AD.",
author = "K. Murase and Toshitaka Nabeshima and Y. Robitaille and R. Quirion and M. Ogawa and K. Hayashi",
year = "1993",
month = "5",
day = "28",
doi = "10.1006/bbrc.1993.1609",
language = "English",
volume = "193",
pages = "198--203",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

NGF Level Is Not Decreased in the Serum, Brain-Spinal Fluid, Hippocampus, or Parietal Cortex of Individuals with Alzheimer′s Disease. / Murase, K.; Nabeshima, Toshitaka; Robitaille, Y.; Quirion, R.; Ogawa, M.; Hayashi, K.

In: Biochemical and Biophysical Research Communications, Vol. 193, No. 1, 28.05.1993, p. 198-203.

Research output: Contribution to journalArticle

TY - JOUR

T1 - NGF Level Is Not Decreased in the Serum, Brain-Spinal Fluid, Hippocampus, or Parietal Cortex of Individuals with Alzheimer′s Disease

AU - Murase, K.

AU - Nabeshima, Toshitaka

AU - Robitaille, Y.

AU - Quirion, R.

AU - Ogawa, M.

AU - Hayashi, K.

PY - 1993/5/28

Y1 - 1993/5/28

N2 - Although the cause of Alzheimers disease (AD) is unknown, nerve growth factor (NGF) has gained attention as a therapeutic agent for the disease. Because NGF maintains the magnocellular cholinergic neurons that are damaged in AD, research interests have been focused on the change in NGF level in patients with AD. This is the first reported study in which human NGF levels were accurately measured and compared between normal and AD samples. We measured NGF levels using enzyme immunoassay (EIA) system for human NGF and found no difference in NGF level in serum, brain-spinal fluid, or brain (hippocampus and parietal cortex) obtained from normal people and patients with AD. These results suggest that a decrease in the NGF level is not a causative factor of AD.

AB - Although the cause of Alzheimers disease (AD) is unknown, nerve growth factor (NGF) has gained attention as a therapeutic agent for the disease. Because NGF maintains the magnocellular cholinergic neurons that are damaged in AD, research interests have been focused on the change in NGF level in patients with AD. This is the first reported study in which human NGF levels were accurately measured and compared between normal and AD samples. We measured NGF levels using enzyme immunoassay (EIA) system for human NGF and found no difference in NGF level in serum, brain-spinal fluid, or brain (hippocampus and parietal cortex) obtained from normal people and patients with AD. These results suggest that a decrease in the NGF level is not a causative factor of AD.

UR - http://www.scopus.com/inward/record.url?scp=0027276502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027276502&partnerID=8YFLogxK

U2 - 10.1006/bbrc.1993.1609

DO - 10.1006/bbrc.1993.1609

M3 - Article

C2 - 8503908

AN - SCOPUS:0027276502

VL - 193

SP - 198

EP - 203

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -